1. Home
  2. ANIX vs HNNA Comparison

ANIX vs HNNA Comparison

Compare ANIX & HNNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

HOLD

Current Price

$2.74

Market Cap

88.8M

Sector

Health Care

ML Signal

HOLD

Logo Hennessy Advisors Inc.

HNNA

Hennessy Advisors Inc.

N/A

Current Price

$10.05

Market Cap

80.0M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
ANIX
HNNA
Founded
1982
1989
Country
United States
United States
Employees
N/A
18
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
88.8M
80.0M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
ANIX
HNNA
Price
$2.74
$10.05
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$8.67
N/A
AVG Volume (30 Days)
158.6K
6.7K
Earning Date
05-27-2026
05-11-2026
Dividend Yield
N/A
5.57%
EPS Growth
12.82
N/A
EPS
N/A
N/A
Revenue
$210,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$8.77
Revenue Growth
N/A
N/A
52 Week Low
$2.32
$8.90
52 Week High
$5.46
$13.19

Technical Indicators

Market Signals
Indicator
ANIX
HNNA
Relative Strength Index (RSI) 51.99 51.58
Support Level $2.38 $9.71
Resistance Level $3.12 $10.28
Average True Range (ATR) 0.19 0.23
MACD 0.04 0.02
Stochastic Oscillator 61.54 59.84

Price Performance

Historical Comparison
ANIX
HNNA

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

About HNNA Hennessy Advisors Inc.

Hennessy Advisors Inc is an investment management company that manages and markets open-end mutual funds branded as the Hennessy Funds. It offers domestic equity, multi-asset sectors, specialty products, and fixed income products. The company earns revenues mainly from investment advisory services and secondarily from shareholder services. Advisory services include managing each fund's portfolio in line with its investment objectives, monitoring compliance and performance, overseeing sub-advisors and other service providers, and handling marketing, distribution, and regulatory reporting. Shareholder services cover investor support and coordination with the fund service provider, with all related fees based on the funds' average daily net asset values.

Share on Social Networks: